Will early detection for breast cancer ever work?

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 190-193

  Esserman, Laura ^a   Ozanne, Elissa ^a   Van't Veer, Laura ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOMA IN SITU; COST EFFECTIVENESS ANALYSIS; FALSE POSITIVE RESULT; GENETIC RISK; HUMAN; MAMMOGRAPHY; NOTE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT;

BIOPSY; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; FEMALE; HUMANS; MASS SCREENING; RISK ASSESSMENT;

EID: 84872021029     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.184689     Document Type: Note

References (15)

1. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 2011;129:165-73.
2. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-92.
3. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-94.
4. American Cancer Society. Americal Cancer Society recommendations for early breast cancer detection. (http://www.cancer.org/healthy/findcancerearly/ womenshealth/non-cancerousbreastconditions/non-cancerous-breast-conditions-a-c- s-recs-for-early-detection (Accessed November 2012).
5. American College of Obstetricians-Gynecologists. Practice Bulletin no. 122: breast cancer screening. Obstet Gynecol 2011;118:372- 82.
6. Buyse M, Loi S, van't Veer L, Delorenzi M, Glas AM, d'Assignies MS, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92. (Pubitemid 44390989)
7. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006;24:3726-34. (Pubitemid 46622311)
8. Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, Gale A. Improving the accuracy of mammography: volume and outcome relationships. J Natl Cancer Inst 2002;94:369-75. (Pubitemid 34257480)
9. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 2004;329:477.
10. Breast Cancer Surveillance Consortium. Evaluating screening performance in practice. 2004. http://breastscreening.cancer.gov/espp.pdf (Accessed November 2012). NIH publication no. 04-5490.
11. Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Rètel VP, Mook S, et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 2011;130:725-34.
12. Ikeda DM, Andersson I, Wattsgard C, Janzon L, Linell F. Interval carcinomas in the Malmö Mammographic Screening Trial: radiographic appearance and prognostic considerations. AJR Am J Roentgenol 1992;159:287-94.
13. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, et al. Locally advanced breast cancers are more likely to present as interval cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat 2011;132:871-9.
14. Ozanne EM, Klemp JR, Esserman LJ. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J 2006;12:103-13.
15. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.